NCT06532084View on ClinicalTrials.gov

Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

PHASE2RecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Acute Myeloid Leukemia, in RelapseMyelodysplastic SyndromesChronic Myeloid LeukemiaMyeloproliferative Neoplasm
Interventions
DRUG

Sorafenib

Sorafenib 200 mg bid for 168 days starting in the time fram between engraftment with neutrophils \> 1.0 x 10\^9/L, white blood cells\> 1.5 x 10\^9/L, platelets\> 1.5 x 10\^9/L and day+100 after allogeneic hematopoietic cell trnaplantation

Trial Locations (1)

197022

RECRUITING

RM Gorbacheva Research Institute, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER